- Trials with a EudraCT protocol (184)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
184 result(s) found for: Immunoglobulin M.
Displaying page 1 of 10.
EudraCT Number: 2009-012036-32 | Sponsor Protocol Number: IGNG-0724 | Start Date*: 2009-07-30 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: SAFETY STUDY OF IGNG, A NEW LIQUID PREPARATION OF HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE, WHEN ADMINISTERED TO PRIMARY IMMUNODEFICIENT PATIENTS, AT A PROGRESSIVELY INCREASED FLOW RATE | |||||||||||||
Medical condition: PRIMARY IMMUNODEFICIENCY | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001545-20 | Sponsor Protocol Number: mRNA-1647-P104 | Start Date*: 2024-05-09 |
Sponsor Name:ModernaTX, Inc. | ||
Full Title: A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age... | ||
Medical condition: Cytomegalovirus infection | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2018-004109-21 | Sponsor Protocol Number: V114-029 | Start Date*: 2021-06-10 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED) | |||||||||||||
Medical condition: Prevention of pneumococcal disease associated with serotypes included in the vaccine. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003686-36 | Sponsor Protocol Number: AR13001 | Start Date*: 2021-07-19 |
Sponsor Name:Finnish Defence Forces | ||
Full Title: Immune response to SARS-CoV-2 vaccines and its clinical significance in the Finnish Defence Forces | ||
Medical condition: Immune response induced by SARS-CoV-2 vaccination. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000479-28 | Sponsor Protocol Number: LTS13932 | Start Date*: 2015-08-17 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase II Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | |||||||||||||
Medical condition: Acute Myeloid Leukemia NOS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004185-34 | Sponsor Protocol Number: 54767414MMY2065 | Start Date*: 2019-05-29 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Mu... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) DK (Completed) NL (Prematurely Ended) FR (Ongoing) ES (Ongoing) PL (Completed) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001635-91 | Sponsor Protocol Number: ODX-MM-001 | Start Date*: 2022-08-10 | |||||||||||
Sponsor Name:DexTech Medical AB | |||||||||||||
Full Title: A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001205-16 | Sponsor Protocol Number: 54767414SMM3001 | Start Date*: 2017-10-18 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma | |||||||||||||
Medical condition: Smoldering multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Ongoing) ES (Ongoing) NO (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001842-34 | Sponsor Protocol Number: DOXIL-MMY-3001 | Start Date*: 2004-11-29 |
Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development | ||
Full Title: A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | ||
Medical condition: Recurred or relapsed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002400-26 | Sponsor Protocol Number: 64407564MMY1001 | Start Date*: 2019-02-06 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Ongoing) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004194-12 | Sponsor Protocol Number: CS-BM32-nasal-001 | Start Date*: 2012-10-23 |
Sponsor Name:Medizinische Universität Wien, HNO Klinik | ||
Full Title: The effect of BM32, a recombinant hypoallergenic vaccine for immunotherapy of grass pollen allergy, on immunoglobulin levels in nasal secretions of patients suffering from seasonal allergic rhinitis | ||
Medical condition: Grass pollen allergy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001534-29 | Sponsor Protocol Number: CYD05 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Subjects Aged 2 to 45 Years in the Philippines | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001706-17 | Sponsor Protocol Number: CYD06 | Start Date*: 2014-05-26 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Subjects Aged 2 to 45 Years in Mexico | ||
Medical condition: Prevention of symptomatic dengue disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-004346-42 | Sponsor Protocol Number: 3150-301-008 | Start Date*: 2019-09-10 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikuma... | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BE (Not Authorised) IT (Prematurely Ended) SK (Prematurely Ended) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002054-55 | Sponsor Protocol Number: PXD101-301-G | Start Date*: 2006-01-12 |
Sponsor Name:Topotarget A/S | ||
Full Title: A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma | ||
Medical condition: Patients in relapse from prior treatment, with histologically and otherwise verified diagnosis of multiple myeloma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000330-19 | Sponsor Protocol Number: 64407564MMY1002 | Start Date*: 2019-09-27 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001618-27 | Sponsor Protocol Number: EMN14/54767414MMY3013 | Start Date*: 2017-05-19 | |||||||||||
Sponsor Name:European Myeloma Network (EMN) | |||||||||||||
Full Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy Wi... | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) ES (Ongoing) BE (Ongoing) DE (Ongoing) CZ (Ongoing) DK (Completed) FR (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015507-52 | Sponsor Protocol Number: CLBH589D2308 | Start Date*: 2009-11-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma | |||||||||||||
Medical condition: Multiple Myeloma (MM), relapsed or relapsed-and-refractory | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) IT (Completed) FR (Completed) ES (Completed) CZ (Completed) PL (Completed) GB (Completed) AT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001563-21 | Sponsor Protocol Number: IM-T-hLL2-18 | Start Date*: 2005-02-02 |
Sponsor Name:Immunomedics, Inc. | ||
Full Title: A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia | ||
Medical condition: Waldenström's Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chroni... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001231-29 | Sponsor Protocol Number: 2005-01-02 | Start Date*: 2005-09-08 |
Sponsor Name:Dept of Transplantation Surgery B 56, Karolinska University Hospital, Huddinge | ||
Full Title: A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATI... | ||
Medical condition: Chronic renal failure patients who are receiving a kidney transplant. Different immunosuppressive protocls are awailable. However, current strategies for the medical management of transplant patie... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.